AI Drug Discovery for Pharma and Biotech

Drug discovery

1

drug

With orphan designation

Overview

Rare female infertility encompasses conditions such as congenital uterine anomalies (e.g., septate uterus), premature ovarian insufficiency, severe endometriosis, and genetic disorders (e.g., Turner syndrome). These etiologies often require specialized diagnostic approaches, including imaging and genetic testing, and may involve advanced assisted reproductive technologies (ART) or surgical interventions for management [4][5][11][16].

Population

  • Affects ~16.2% of women with uterine abnormalities (polyps, fibroids, adhesions) and 10–15% with tubal disorders linked to untreated infections or endometriosis [4][5][14].

  • Premature ovarian insufficiency impacts 1% of women under 40, while severe endometriosis affects ~30–50% of infertile women [9][16].

Burden

  • Psychological distress, social stigma, and financial strain due to high treatment costs (e.g., IVF cycle costs $12,000–$25,000) [12][16][18].

  • Delayed diagnosis (e.g., endometriosis: 7–8 years average delay) exacerbates complications like chronic pain and reduced quality of life [16][20].

  • Disproportionate access barriers in low-resource settings, where <30% of countries prioritize fertility care [4][10].

Therapies

  • Surgical correction (e.g., hysteroscopic resection for septate uterus) [5][11].

  • ART: IVF for tubal or ovarian causes; ovulation induction with clomiphene/gonadotropins for ovulatory dysfunction [3][11][19].

  • Donor eggs or surrogacy for genetic or irreversible ovarian failure [10][16].

Categories: rare infertility disorders

Research Papers

303 drug discovery papers about Rare female infertility, with 3 first-in-class and 1 next-in-class emerging drug candidate forecasted to outperform the average preclinical success rate. Recent publications:

303 drug discovery papers about Rare female infertility, with 3 first-in-class and 1 next-in-class emerging drug candidate forecasted to outperform the average preclinical success rate. Recent publications:

categories:

Small molecules

small molecules
2026-09-23 | Arimoclomol-loaded Pluronic F127 nanomicelles in experimental endometriosis: drug incorporation, in vitro release, and early morphological and histological responses.

Endometriosis is a chronic, estrogen-dependent inflammatory disease characterized by ectopic endometrial-like glands and stroma, persistent pelvic inflammation, pain, infertility, and frequent recurrence. The limited availability of nonhormonal and lesion-directed therapies supports the investigation of alternative pharmacological mechanisms and regional drug-delivery strategies. Arimoclomol is a co-inducer of the endogenous heat-shock response with the capacity to amplify stress-dependent proteostasis, whereas Pluronic F127 is an amphiphilic PEO-PPO-PEO copolymer that forms drug-associated micellar assemblies in aqueous media. This exploratory study evaluated the physicochemical properties, in vitro release profile, and early biological response to arimoclomol-loaded Pluronic F127 nanomicelles in an autologous-transplantation rat model of endometriosis. The formulation was prepared by dispersing 30 mg of arimoclomol in 2 mL of Pluronic F127 at 20% (w/v), followed by stirring and ultrasonication under cooling. Because no centrifugation, filtration, dialysis, lyophilization, or other drug-removal step was applied after incorporation, the nominal process loading efficiency was 100%, based on formulation mass balance. The corresponding theoretical drug content was 6.98% w/w of total formulation solids and 7.5% w/w relative to the polymer mass. Drug-polymer association was supported by scanning electron microscopy coupled to energy-dispersive X-ray spectroscopy, Raman spectroscopy, and UV-Vis spectroscopy. In vitro dialysis at 37 °C showed a rapid increase in acceptor-medium arimoclomol concentration, reaching 14.33 ± 0.18 µg/mL at 2 h, followed by a progressive decline, with arimoclomol remaining detectable at 72 h (2.76 ± 0.04 µg/mL). Endometriosis was induced in ten female Wistar rats. On day 16, animals received a single intraperitoneal administration of arimoclomol-loaded nanomicelles (n = 4), empty nanomicelles (n = 3), or free arimoclomol (n = 3). The arimoclomol dose was 3 mg/animal, equivalent to approximately 14.7-16.8 mg/kg according to the recorded body-weight range. Twenty-four hours after treatment, representative lesions from the loaded-nanomicelle group appeared smaller macroscopically and showed mildly atrophic glands, stromal disorganization, and less prominent inflammatory infiltration than representative lesions from the empty-carrier and free-drug groups. All clinical welfare scores remained zero, and no overt short-term intolerance was observed. These findings demonstrate nominal quantitative drug retention based on process mass balance, a biphasic in vitro release pattern, and an early treatment-associated morphological and histological response. These preliminary findings require confirmation in larger, blinded, power-calculated studies with quantitative lesion endpoints, mechanistic biomarkers, lesion-specific pharmacokinetics, and longitudinal safety assessment.

Open article ↗



2026-09-14 | [A novel CYP19A1 variant causing aromatase deficiency in a family: case report and literature review].

Aromatase deficiency is a rare autosomal recessive disorder of estrogen biosynthesis caused by pathogenic variants in the CYP19A1 gene, located on chromosome 15q21.2. Maternal virilization during pregnancy serves as an important diagnostic clue. Affected females may present with virilized external genitalia at birth, and later in life may develop primary amenorrhea, ovarian cysts or ovarian dysplasia, delayed epiphyseal closure, and reduced bone mineral density. Herein, a family with aromatase deficiency admitted to the Department of Endocrinology and Metabolism at the Affiliated Hospital of Qingdao University in October 2020 is reported. The female proband exhibited virilized external genitalia since birth, along with hirsutism, acne, and voice deepening. Laboratory findings revealed low estrogen levels, hyperandrogenemia, and elevated follicle-stimulating hormone and luteinizing hormone levels. Genetic testing identified a homozygous CYP19A1 variant. After estrogen replacement therapy, the patient achieved regular menstrual cycles, with improvements in hirsutism and acne. A literature review identified 35 female patients carrying 28 distinct CYP19A1 variants, most of whom exhibited characteristic clinical manifestations. Whole-exome sequencing in the present case revealed a homozygous CYP19A1 variant, c.293_296+1delinsTTA, which has not been previously reported. Given the low incidence of aromatase deficiency, individualized treatment is cruical for optimal outcomes. Genetic testing plays a pivotal role in establishing a definitive diagnosis and guiding personalized management.

Open article ↗



2026-09-06 | Successful pregnancy after in vitro fertilization-embryo transfer in a patient with cytochrome P450 oxidoreductase deficiency and a double uterus: Case report.

Cytochrome P450 oxidoreductase deficiency (PORD) is a rare autosomal recessive disorder caused by mutations in the POR gene, leading to impaired steroid hormone synthesis and a wide range of multisystem abnormalities. The condition is often associated with reproductive malformations and endocrine disorders, presenting clinically with symptoms such as infertility, menstrual irregularities, and adrenal dysfunction, and may be accompanied by skeletal malformations. Only a very limited number of patients have achieved successful pregnancies through assisted reproductive technology, and there is currently no standardized treatment strategy. A 29-year-old woman presented with "7 years of infertility without contraception." Genetic analysis identified compound heterozygous POR mutations (c.1820A>G/c.1474G>A), confirming PORD. Pelvic imaging revealed uterus didelphys. Endocrine evaluation demonstrated insulin resistance and adrenal dysfunction, and the patient fulfilled the diagnostic criteria for polycystic ovary syndrome. Following unsuccessful long-protocol ovulation induction, a modified gonadotropin-releasing hormone antagonist protocol was implemented with metformin co-treatment for insulin sensitization. Stepwise glucocorticoid therapy (oral prednisone 5 mg/day → dexamethasone 0.5 mg/day → transition to hydrocortisone 20 mg/day during pregnancy) was administered for adrenal progesterone regulation. All embryos underwent vitrification, with subsequent single frozen-thawed blastocyst transfer. Ovarian stimulation yielded 24 oocytes, resulting in 7 blastocysts. Successful singleton implantation was achieved. The pregnancy progressed without maternal metabolic or fetal complications, culminating in term delivery (39 weeks and 4 days) of a healthy male neonate (birth weight 3250 g, Apgar scores 9/10). This case demonstrates that pregnancy attainment in complex PORD requires protocol individualization using gonadotropin-releasing hormone antagonists to mitigate premature luteinization, dynamic glucocorticoid titration to control adrenal steroid excess, and metabolic optimization addressing insulin resistance. The co-occurrence of POR mutations should be investigated in assisted reproductive technology failures with polycystic ovary syndrome-like presentations, particularly when accompanied by skeletal or genital tract anomalies.

Open article ↗



2026-07-31 | Utility of homoeopathic medicines in management of cases of PCOS - A retrospective hospital based study

Introduction: This comprehensive study evaluates the effectiveness of Homoeopathic medicines in the management of PCOS cases through a hospital based retrospective study & identifies frequently used Homoeopathic medicines and the prominent miasm in the reported outcomes. PCOS is a multisystem disorder on the rise in the last few years. It is marked by irregular menses, Hyperandrogenism, hirsutism, acne, infertility with global prevalence of 6% to 26%.Homoeopathy is a holistic system, which helps in this endocrine disorder. Aim:To identify utility of homoeopathic medicines,the predominant miasm in cases of PCOS/PCOD through retrospective hospital based study. Materials and methods: It includes analysis of 792 female patients treated in the last 3 years (January 2021 - January 2024) of reproductive age (12 to 50 years) from a Govt. homoeo Medical College & Hospital, Rajamahendravaram, India. The data collected in specifically designed formats the master charts and details shown in the form of Tables and charts. Results: Most patients presented with irregular menses, dysmenorrhea, acne, weight gain, hirsutism, and infertility. Individualized homoeopathic medicines, mainly polycrests were frequently used with positive outcomes including menstrual regularization in over 60% of cases. Antimiasmatics and rare remedies were also applied. The predominant miasm identified through retrospective study was psoro-sycotic. Conclusion: This retrospective study data indicates individualized/constitutional homoeopathic medicines like polycrests playing a significant role in managing PCOS symptoms, particularly menstrual irregularities and infertility. The predominant miasm identified is Psorosycotic, antimiasmatics complement treatment success. It shows that polycrests are proven effective in treating PCOS. There is a requirement for well documented case formats in hospital settings, well planned, pragmatic research studies and RCTs.

Open article ↗



2026-07-31 | Therapeutic Roles and Safety Profiles of Non-Vitamin Antioxidant Supplements in Female Infertility: A Narrative Review.

Treatment of female infertility consists different strategies including metabolic, hormonal and surgical therapeutic modalities. Non-vitamin supplements with antioxidant activity as carnitines, Inositols, Poly Unsaturated Fatty Acids (PUFAs), coenzyme Q10 and melatonin are among those with most popularity, but their prescription may confer some warnings. This review narrates the antioxidant mechanism of these supplements, beside their effect on outcomes of infertility treatment while considering side effects, warnings and ranges of doses. Carnitines are used for energy production and fat metabolism, while they have anti-aging and antioxidant effects. Supplementation with carnitines improve obesity outcomes, especially in Poly Cystic Ovarian Disease (PCOS) patients. Rare cases have shown increasing risk of seizure with levocarnitine. Coenzyme Q10 (Ubiquinone) has shown benefit in patients with PCOS or poor ovarian responders. It significantly increased live birth rate and the side effects are minimal even in higher doses. Poly Unsaturated Fatty Acids (PUFAs) have shown impact on follicular development and embryo quality. The hazard is increasing lipid low density lipoprotein (LDL) in high doses. Use of inositols in female infertility treatment is due to its metabolic effect and insulin resistance in PCOS patients resulting in decreasing use of gonadotropins. They have produced acceptable results about count of follicles and oocyte quality. Hypoglycemic effects of inositols have been reported as side effect, especially in combination with other hypoglycemic agents. Melatonin can increase the clinical pregnancy rate, and improve the outcomes about oocyte and quality of embryo via receptor- and non-receptor- action. Dizziness, drowsiness, and headache are reported in higher doses of melatonin. The attitude that all supplement can be prescribed without restriction endangers susceptible patients. Hence, increasing our knowledge about efficacy and safety profile can help individualize prescription of supplements for female infertility.

Open article ↗



proteins
2026-08-01 | EP1877 - LBA_ECE_1047 - FSH resistance syndrome in a young woman with primary amenorrhea

Abstract Introduction FSH-resistant ovary syndrome is a rare cause of primary or secondary amenorrhea. It is characterized by menopausal levels of FSH and LH, low estradiol levels, normal anti-Müllerian hormone (AMH) levels, and the presence of immature ovarian follicles with impaired maturation due to mutations in the FSH receptor (FSHR) gene. Patients present with anovulation and infertility and are commonly diagnosed with premature ovarian insufficiency. Case Presentation A 32-year-old woman with a history of primary amenorrhea presented for fertility evaluation. The patient had normal secondary sexual characteristics and had been treated with cyclic hormonal therapy with estrogen and progesterone since adolescence. Laboratory evaluation showed a normal female karyotype, elevated FSH/LH levels (101.9 mIU/mL and 41.4 mIU/mL, respectively), low estradiol levels (17.2 pg/mL), and normal AMH levels (1.7 ng/mL). Transvaginal ultrasound demonstrated normal internal genitalia, with an antral follicle count of 10. There was no known family history of infertility. The patient underwent ovarian stimulation with follitropin alfa 300 IU, without follicular development. Genetic testing revealed a novel homozygous missense variant in the FSHR gene, c.1412T>G p.(Ile471Ser), classified as likely pathogenic, confirming the diagnosis of FSH resistance syndrome. The patient was referred for further specialized assisted reproductive treatment. Conclusions FSH resistance should be suspected in women of reproductive age presenting with primary or secondary amenorrhea, when elevated FSH and LH levels are found alongside low/normal estradiol levels, but preserved ovarian reserve. The combination of clinical evaluation, laboratory findings, and genetic testing enables early recognition and appropriate counseling. In these cases, conventional ovarian stimulation has low likelihood of success, and recommended reproductive strategies include in vitro maturation (IVM) of oocytes and oocyte donation.

Open article ↗



2026-07-30 | Hemoperitoneum after oocyte retrieval in women undergoing ART: A 2017-2022 retrospective cohort study with a historical comparison to 1996-2016.

To estimate the incidence and predictors of severity-defined hemoperitoneum after oocyte retrieval in a contemporary 2017-2022 cohort, and to place these findings in context with the center's previously published 1996-2016 experience. Retrospective cohort study including all 13,192 oocyte retrieval procedures performed at a single fertility center from January 2017 to December 2022 in 9,346 women. The primary endpoint was documented hemoperitoneum associated with hemoglobin decrease ≥ 2 g/dL and/or hospital admission, surgery or blood transfusion. The 1996-2016 cohort was retained only as an aggregate historical comparator. Predictors were estimated with robust Poisson regression clustered by patient identifier. Severity-defined hemoperitoneum was identified among 50 retrievals (0.379 %), including 46 cases with hemoglobin decrease ≥ 2 g/dL, 44 admissions, 20 surgical procedures and 12 transfusions. The contemporary primary endpoint was recorded more frequently than the historical aggregate hemorrhagic comparator (RR 1.67, 95 % CI 1.14-2.46, p = 0.010), whereas surgery did not differ significantly (RR 1.81, 95 % CI 0.97-3.36, p = 0.069). In the primary contemporary model, lower BMI (RR 0.80 per kg/m2, 95 % CI 0.73-0.88, p < 0.001), higher AMH (RR 1.08, 95 % CI 1.02-1.14, p = 0.010) and longer total retrieval time (RR 1.03 per minute, 95 % CI 1.00-1.06, p = 0.044) were associated with severity-defined hemoperitoneum. Hemoperitoneum after oocyte retrieval was rare, but associated with substantial morbidity when it occurred. Lower BMI and higher AMH were the main patient-level risk markers. Total retrieval time remained modestly associated with the risk, and should be interpreted as a marker of ovarian response and procedural complexity. The higher rate observed in the contemporary cohort should be interpreted cautiously, as surgery did not increase significantly. NCT05895227, May 31st, 2023.

Open article ↗



2026-02-23 | The Clinico-radiological Perspective of Kartagener's Syndrome.

Kartagener's syndrome is a rare autosomal recessive genetic disorder, a subset of primary ciliary dyskinesia. It comprises the triad of situs inversus totalis, bronchiectasis, and chronic paranasal sinusitis. The incidence is 1:30,000 live births, while the male: female ratio is 1:1. Most patients of Kartagener's syndrome present in early childhood with common symptoms of frequent colds, chronic cough with excessive production of purulent sputum, and recurrent lower respiratory tract infections affecting respiratory functions. Kartagener's syndrome commonly presents as infertility in males and subfertility in females. We present the clinical and radiological findings in a patient of Kartagener's syndrome referred to us with recurrent lower respiratory tract infections.

Open article ↗



2026-01-31 | TURNER SYNDROME: CLINICAL FEATURES AND CONTEMPORARY DIAGNOSTIC APPROACHES

Turner syndrome (TS) is a rare chromosomal disorder affecting approximately 1 in 2,500–3,000 live female births and caused by complete or partial monosomy of one X chromosome, most commonly presenting as a 45, X karyotype or mosaic forms. The syndrome is associated with a wide spectrum of clinical manifestations, including short stature, ovarian dysgenesis, delayed puberty, infertility, and congenital anomalies, particularly cardiovascular malformations such as coarctation of the aorta and bicuspid aortic valve.

Open article ↗



2025-11-21 | Turner disease: A contemporary clinical approach

Turner syndrome (TS) is a rare genetic disorder in females caused by partial or complete loss of one X chromosome. It presents with multisystem clinical manifestations that require lifelong multidisciplinary care and monitoring. Phenotypically, TS is characterized by short stature, short neck with lateral skin folds (pterygium colli), low-set ears, and a low posterior hairline. Clinically, it is associated with cardiovascular diseases (CVD) and primary hypogonadism. The diagnosis of TS is based on clinical presentation and genetic analysis, with early prenatal detection possible. In newborns, TS should be suspected in the presence of oedema of the hands and feet. Short stature becomes evident in early childhood, while delayed puberty and primary amenorrhea are common later findings. CVDs may be congenital or acquired; coarctation of the aorta is a key diagnostic sign, whereas aortic dissection and rupture of an aortic aneurysm are life-threatening complications. Most women with TS have primary hypogonadism and high infertility rates. Spontaneous pregnancies are rare, and fertility preservation options, such as oocyte or embryo cryopreservation, should be considered early. Associated autoimmune diseases, kidney anomalies, liver disorders, and hearing loss are also common. Hormone replacement therapy is essential for pubertal induction, maintenance of general health, and prevention of long-term complications of untreated hypogonadism. Due to numerous comorbidities and variable phenotypes, an individualized multidisciplinary approach is required. With early diagnosis, appropriate management, and psychosocial support, individuals with TS can lead a good quality of life despite ongoing health risks.

Open article ↗



cell therapies
2026-03-10 | Reproductive Challenges of the Ageing Female: A Comprehensive Narrative Review.

Changes in societal norms over the last few decades have resulted in novel family planning trends, notably delayed childbearing and increased maternal age at the birth of the first child. Despite advances in reproductive medicine, ageing poses significant challenges. Natural conception in women ≥ 45 years of age is rare, with high rates of pregnancy loss, and assisted reproduction using autologous oocytes yields limited success. Oocyte donation offers higher live birth rates, exceeding 50%. Elective oocyte cryopreservation could aid in family planning; nevertheless, its success depends on the age at which cryopreservation is performed. These facts highlight the correlation between advancing age and a decline in oocyte quality and quantity. An age-related decline in endometrial receptivity could pose an additional barrier, although the evidence remains controversial. Furthermore, pregnancies in older women carry high risks for both the mother and child, which should be considered before assisted conception attempts. This comprehensive narrative review examines the advancements in assisted reproductive technology that have expanded the possibilities for delayed childbearing, while underlining at the same time the major challenges in the field. Innovations such as ovarian tissue cryopreservation and stem cell-based therapies have the potential to reshape reproductive options for these women. However, thorough counselling and tailored management remain of paramount importance.

Open article ↗



2025-12-12 | The Doing/Undoing of MRKH and the Doing of Gestational Pregnancy and Gender Through Uterus Transplants.

Women with the rare Mayer-Rokitansky-Kuster-Hauser (MRKH) syndrome are born without a uterus. Following international interviews with 34 women with MRKH and 15 surgeons and specialists, we explore how the usually invisible condition of MRKH is made visible and "done" through biomedicine. MRKH is highly medicalized, with much work undertaken to make MRKH bodies fit heteronormative standards. Some people with MRKH prefer to define themselves as intersex. Others undertake uterus transplants (UTx), to experience menstruation, gestation, and birth. UTx reconstructs their bodies to heteronormative expectations at the same time as it reinforces gendered identity as normative women, and potentially as mothers.

Open article ↗



2025-11-26 | Endometrial Injury and Its Rescue by Mesenchymal Stem Cells Is Dependent on Estrous Cycle Phase.

Asherman Syndrome (AS) is caused by injury to the endometrium leading to uterine scarring, decreased menstruation and infertility; it typically occurs after surgical curettage of the uterus. AS is treated surgically albeit with limited success. Administration of bone marrow-derived mesenchymal stem cells (MSCs) has recently been demonstrated to restore uterine function in AS; however, there is no data available on the role of the estrous cycle phase on outcomes. Here, we describe endometrial injury during estrus or diestrus, its differential effect on fertility, and its response after bone marrow MSC treatment to reverse the infertility in a murine model. Endometrial injury in the estrus phase did not affect fertility outcomes whereas injury in the diestrus phase resulted in infertility. Bone marrow (BM)-derived MSC treatment without injury in the estrus or diestrus phase did not affect the pregnancy outcomes. BM MSC treatment following endometrial injury in the diestrus phase restored fertility. Immunofluorescence analysis revealed that vimentin or cytokeratin-positive BM-derived cells in the uterus were extremely rare. BM MSC treatment after injury increased CD45+ cells, indicating a role for immunomodulation in endometrial repair. Finally, qRT-PCR showed that Ccl3, Il-1β and Mmp3 gene expression was significantly higher in the endometrium of the injury + BM MSC group than in other groups. In summary, injury to the endometrium during the diestrus phase results in infertility that can be restored by the treatment of BM MSCs. The therapeutic effect of BM MSCs on the endometrium appears to be mediated primarily by immunomodulation rather than BM MSC engraftment.

Open article ↗



2025-11-18 | The Danish Turner Syndrome Cryopreservation study: PROTOCOL for a prospective cohort Study on reproductive outcomes after ovarian tissue cryopreservation in girls with Turner syndrome.

BACKGROUND: Turner syndrome (TS) is a chromosomal disorder caused by complete or partial loss of one X chromosome, resulting in a high risk of premature ovarian insufficiency (POI) and infertility. While the underlying mechanisms are not fully understood, oocyte loss is known to begin in fetal life and continue throughout childhood, often leading to ovarian failure before the onset of puberty. Ovarian tissue cryopreservation (OTC) offers a potential method to preserve fertility in girls with TS, but the procedure remains experimental in this group. To date, only three cases of autotransplantation have been reported, and no live births have occurred in women with TS. Moreover, predictors of residual ovarian function and eligibility for OTC are poorly defined, and the long-term effects of unilateral oophorectomy in girls with already limited ovarian reserve are unknown. OBJECTIVE: To investigate long-term reproductive outcomes following OTC in girls with TS. METHODS: The Danish Turner Syndrome Cryopreservation Study is a nationwide, prospective cohort study with long-term follow-up, combining observational and interventional elements. Girls with TS aged 2–17 years are invited to participate. As ovarian reserve is depleted before adulthood in most girls with TS, all participants undergo ovarian function assessment to evaluate the likelihood of remaining viable follicles. If follicles are deemed present, unilateral OTC may be offered. The primary outcome is the number of pregnancies, miscarriages, and live births following autotransplantation of cryopreserved and thawed ovarian tissue in adulthood. Secondary objectives include identifying early predictors of POI, assessing the impact of oophorectomy on ovarian function and pubertal progression, and exploring molecular mechanisms of ovarian dysgenesis through genetic and epigenetic analyses of ovarian and peripheral tissues. Recruitment began in January 2024 and is ongoing at three university hospitals across Denmark. Follow-up is expected to continue until 2050. CONCLUSION: This study addresses a critical gap in fertility preservation for girls with TS by evaluating the feasibility and long-term outcomes of OTC. The findings will improve understanding of POI progression, refine selection criteria for OTC, and support evidence-based counselling for girls with TS and their families. TRIAL REGISTRATION: ClinicalTrials.gov, NCT05740579. Registered 13 February 2023. https//clinicaltrials.gov/study/NCT05740579.

Open article ↗



2025-08-20 | A rare association of Craniopharyngioma and Meyer-Rokitansky-Kuster-Hauser Syndrome in a patient with primary amenorrhea and delayed puberty – A Case Report

Background: Meyer-Rokitansky-Kuster-Hauser Syndrome (MRKH) is a congenital abnormality of the uterus and the upper two-thirds of the vagina in women showing normal development of secondary sexual characteristics with a normal karyotype of 46, XY. Craniopharyngioma is a rare intracranial neoplasm found in seller/suprasellar region with two distinct histologic phenotypes – adamantinoma Tous and papillary. It has insidious onset of symptoms and presents as headache, visual impairment and hormonal imbalances secondary to compression of adjacent pituitary manifesting commonly as sexual dysfunction in adults and growth failure in children. This case report presents a 20 years female with primary amenorrhea and absence of secondary sex characteristics, headache and visual field defect who was subsequently diagnosed as adamant nous craniopharyngioma with multiple pituitary hormones deficiency with Type 1 MRKH. Patient underwent transsphenoidal resection and replacement of levothyroxine and corticosteroid with further plan of reassessing pituitary gonadal axis, creation of a neovagina, addressing puberty induction and infertility (in vitro fertilization and surrogacy). It is too early to say that there may be an association between craniopharyngioma and MRKH. Whether craniopharyngioma and MRKH share a similar etiology is unclear. With increasing genetic testing, in the future, we may get some correlation.

Open article ↗



gene therapies
2023-11-21 | Homozygous missense variant in MEIOSIN causes premature ovarian insufficiency.

Are variants of genes involved in meiosis initiation responsible for premature ovarian insufficiency (POI)? A MEIOSIN variant participates in the pathogenesis of human POI by impairing meiosis due to insufficient transcriptional activation of essential meiotic genes. Meiosis is the key event for the establishment of the ovarian reserve, and several gene defects impairing meiotic homologous recombination have been found to contribute to the pathogenesis of POI. Although STRA8 and MEIOISN variants have been found to associate with POI in a recent study, the condition of other meiosis initiation genes is unknown and direct evidence of variants participating in the pathogenesis of POI is still lacking. This was a retrospective genetic study. An in-house whole exome sequencing (WES) database of 1030 idiopathic POI patients was screened for variations of meiosis initiation genes. Homozygous or compound heterozygous variations of genes involved in meiosis initiation were screened in the in-house WES database. The pathogenicity of the variation was verified by in vitro experiments, including protein structure prediction and dual-luciferase reporter assay. The effect of the variant on ovarian function and meiosis was demonstrated through histological analyses in a point mutation mouse model. One homozygous variant in MEIOSIN (c.1735C>T, p.R579W) and one in STRA8 (c.258 + 1G>A), which initiates meiosis via the retinoic acid-dependent pathway, were identified in a patient with idiopathic POI respectively. The STRA8 variation has been reported in the recently published work. For the MEIOSIN variation, the dual-luciferase reporter assay revealed that the variant adversely affected the transcriptional function of MEIOSIN in upregulating meiotic genes. Furthermore, knock-in mice with the homologous mutation confirmed that the variation impacted the meiotic prophase I program and accelerated oocyte depletion. Moreover, the variant p.R579W localizing in the high-mobility group (HMG) box domain disrupted the nuclear localization of the MEIOSIN protein but was dispensable for the cell-cycle switch of oocytes, suggesting a unique role of the MEIOSIN HMG box domain in meiosis initiation. Further studies are needed to explore the role of other meiosis initiation genes in the pathogenesis of POI. The MEIOSIN variant was verified to cause POI by impaired transcriptional regulation of meiotic genes and was inherited by a recessive mode. The function of HMG box domain in MEIOSIN protein was also expanded by this study. Although causative variations in meiotic initiation genes are rare in POI, our study confirmed the pathogenicity of a MEIOSIN variant and elucidated another mechanism of human infertility. This work was supported by the National Key Research & Developmental Program of China (2022YFC2703800, 2022YFC2703000), National Natural Science Foundation for Distinguished Young Scholars (82125014), National Natural Science Foundation of China (32070847, 32170867, 82071609), Basic Science Center Program of NSFC (31988101), Natural Science Foundation of Shandong Province for Grand Basic Projects (ZR2021ZD33), Natural Science Foundation of Shandong Province for Excellent Young Scholars (ZR2022YQ69), Taishan Scholars Program for Young Experts of Shandong Province (tsqn202211371), and Qilu Young Scholars Program of Shandong University. The authors declare no conflict of interest. N/A.

Open article ↗



2019-07-15 | Novel WEE2 gene variants identified in patients with fertilization failure and female infertility.

To determine whether variants in the WEE2 (WEE1 homolog 2, also known as WEE1B) gene, which has been known to function in the formation of pronuclei during fertilization, contribute to fertilization failure. Case-control genetic study. University hospital. Ninety infertile women with repeated cycles of pronucleus formation failure undergoing in vitro fertilization and/or intracytoplasmic sperm injection treatment as well as 200 fertile control women. Genomic DNA was extracted from the peripheral blood. The whole exons of WEE2 were amplified by means of polymerase chain reaction and then Sanger sequencing was performed. Variants analysis of WEE2 gene. We identified five subjects that were subjected to homozygous or compound-heterozygous variants of WEE2: case 1 (from a consanguineous family) with homozygous frameshift variant: c.293_294insCTGAGACACCAGCCCAACC (p.Pro98Pro fsX2); case 2 with homozygous missense variant: c.1576T>G (p.Tyr526Asp); and three cases with compound-heterozygous variants: case 3: c.991C>A (p.His331Asn) and c.1304_1307delCCAA (p.Thr435Met fsX31); case 4: c.341_342 del AA (p.Lys114Asn fsX20) and c.864G>C (p.Gln288His); and case 5: c.1A>G (p.0?) and c.1261G>A (p.Gly421Arg). Besides c.1576T>G (from case 2) and c.864G>C (from case 4), which have been previously reported as rare single nucleotide polymorphisms (SNPs), the other six variants were novel and predicted by software to be deleterious. The parental genotypes of case 1 and case 2 indicated that the detected homozygous variants were inherited in an autosomal recessive mode. All of the detected variants were absent from the control cohort. Novel variants found in WEE2, which is autosomal-recessive inherited, may be related to recurrent pronucleus formation failure and female infertility.

Open article ↗



2018-03-16 | A Novel FOXL2 Mutation Implying Blepharophimosis-Ptosis-Epicanthus Inversus Syndrome Type I.

Blepharophimosis-ptosis-epicanthus inversus syndrome (BPES) is a rare autosomal dominant disease caused by FOXL2 gene mutations, and it is clinically characterized by an eyelid malformation associated (type I) or not (type II) with premature ovarian failure (POF). Functional study of novel mutations is especially critical for female patients, as it may allow the prediction of infertility and early planning of an appropriate therapy. A clinical and molecular genetic investigation was performed in all members of a Chinese family with BPES. Genomic DNA was extracted, and the FOXL2 coding region was sequenced. Subcellular localization was performed by confocal microscopy. Transactivation studies were performed by real-time PCR, dual luciferase reporter assays and electrophoretic mobility shift assays. A novel deletion mutation (C.634_641 del, CCCATGC) between the forkhead domain and the polyalanine domain was found, resulting in a frameshift mutation and a truncated protein. Functional studies showed a strong cytoplasmic mislocalization and abnormal transactivation activity, implying a type I kind mutation with a large chance of infertility. This study identifies that this mutation indicates the probability of developing into POF and shows the importance and necessity of early recognition of BPES type through mutation testing for female patients. Prompt personalized therapy and follow-up is of great clinical significance for female patients carrying this kind of mutation.

Open article ↗



2012-01-12 | Two common polymorphisms in the peroxisome proliferator-activated receptor γ gene may improve fertilization in IVF.

Genetic factors play an important role in women's fertility and embryonic development and may also contribute to the efficacy of assisted reproduction techniques. The aim of this study was to investigate the effect of His447His and Pro12Ala peroxisome proliferator-activated receptor γ (PPARγ) gene polymorphisms on oocytes and fertilization in women undergoing IVF. Follicular fluid and blood samples were obtained from 98 IVF patients referred to Tabriz Alzahra Hospital. Samples were analysed for fatty acid content by gas-liquid chromatography and for polymorphisms of the PPARγ gene using polymerase chain reaction-restriction fragment length polymorphism-based methods. Multiple regression analyses were used to test the independence of associations between the number of mature and fertilized oocytes as outcome variables and the polymorphisms of PPARγ gene. For both polymorphisms, fertilization ratio was significantly (P<0.05) higher in carriers of the rare alleles than homozygous wild-type genotypes. The associations of His447His (P=0.003) and Pro12Ala (P=0.015) polymorphisms remained statistically significant in the multiple regression analyses. This study suggests that the two common gene polymorphisms of PPARγ may improve fertilization in vitro and, thus possibly, female fertility.

Open article ↗



other
2022-08-02 | Biallelic variants in MOS cause large polar body in oocyte and human female infertility.

What is the genetic basis of female infertility involving abnormal oocyte morphology with the production of a large first polar body (PB1)? The homozygous missense variant (c.791C>G) and compound missense variants (c.596A>T and c.875C>T) in MOS proto-oncogene, serine/threonine kinase (MOS) (Online Mendelian Inheritance in Man (OMIM) reference: 190060; NM_005372.1) are responsible for abnormal oocyte morphology with the production of a large PB1 to cause infertility in women. MOS, an oocyte-specific gene, encodes a serine/threonine-protein kinase that directly phosphorylates mitogen-activated protein kinase (MAPK) kinase (MEK) to activate MAPK (also called extracellular-signal-regulated kinase (ERK)) signal cascade in the oocyte. Female mice lacking Mos remained viable, but infertile because of oocyte symmetric division, spontaneous parthenogenetic activation and early embryonic arrest. Recently, two independent studies demonstrated that female infertility with early embryonic arrest and fragmentation can be caused by biallelic mutations in MOS. However, so far, MOS variants have not been associated with the phenotype of large PB1 extrusion in human oocytes to contribute to female infertility. Two independent infertile families characterized by the presence of large PB1 in oocytes were recruited between December 2020 and February 2022. Genomic DNA was extracted from the peripheral blood samples of the subjects for whole-exome sequencing. Pedigree analysis was validated by Sanger sequencing. Then, the pathogenic effects of the MOS variants on MOS protein properties and ERK1/2 activation were determined in HEK293 cells and mouse oocytes. We identified three rare missense variants in MOS, including a homozygous missense variant (c.791C>G) from Patient 1 in Family 1 and two compound missense variants (c.596A>T and c.875C>T) from twin sisters in Family 2. The MOS variants followed a recessive inheritance pattern in infertile patients. All three patients displayed a high percentage of large PB1 extrusion in the oocytes. The three MOS variants could not activate MEK1/2 and ERK1/2 in oocytes and HEK293 cells. In addition, when compared with wild-type MOS, the MOS variants decreased the MOS protein level and attenuated the binding capacity with MEK1. Microinjection of wild-type human MOS complementary RNAs (cRNAs) reversed the symmetric division of oocytes after siMos treatment. In contrast, the three MOS variants demonstrated no rescuing ability. N/A. Owing to the scarcity of human oocyte samples and the associated ethical restrictions, we could not perform the rescue attempt for the study patients. Our findings expand the genetic and phenotypic spectrum of MOS variants in causing female infertility. Our study findings facilitate the early genetic diagnosis of abnormal oocyte morphology characterized as large PB1 that eventually causes infertility in women. This study was supported by the National Natural Science Foundation of China (82071640 and 82001633), Natural Science Foundation of Zhejiang Province (LD22C060001), the Key Projects Jointly Constructed by the Ministry and the Province of Zhejiang Medical and Health Science and Technology Project (WKJ-ZJ-2005), China Postdoctoral Science Foundation (2020M682575 and 2021T140198), the Changsha Municipal Natural Science Foundation (kq2007022) and Hunan Provincial Grant for Innovative Province Construction (2019SK4012). None of the authors declare any competing interests. N/A.

Open article ↗



2022-05-30 | Obstetrical complications and outcome in patients with endometriosis.

Endometriosis is a disease that has a profound impact on the quality of life of women, due to the associated chronic pelvic pain, dysmenorrhea, dyspareunia and infertility. However, even getting long-awaited pregnancy (often after assisted reproductive technologies), patients with endometriosis have a high risk of obstetric complications, such as miscarriage, preterm birth, preeclampsia, placental abnormalities, hemorrhage in labor, birth of small for gestational age infants, stillbirth and higher cesarean section rate. In addition, during pregnancy acute complications of endometriosis may occur, such as spontaneous hemoperitoneum, which is rare but life-threatening conditions that in most cases require surgical intervention. The mechanisms of the observed complications in pregnant women with endometriosis are not fully understood. This review presents literature data and personal considerations on the effect of endometriosis on pregnancy outcome and the occurrence of complications, as well as their possible underlined mechanisms. Based on this, we proposed ways to reduce the risk of obstetric complications in pregnant women with a history of endometriosis.

Open article ↗



2022-03-11 | Involvement of chemerin and CMKLR1 in the progesterone decrease by PCOS granulosa cells.

Polycystic ovarian syndrome (PCOS) is the main cause of infertility in women. It is frequently associated with reduced progesterone production by human luteinised granulosa cells (hlGCs). However, the molecular mechanisms involved in these steroidogenesis alterations in PCOS patients are unclear. In a dihydrotestosterone-induced PCOS mouse model, steroid production is maintained in the setting of chemokine-like receptor 1 (Cmklr1) knockout. Thus, chemerin and chemerin receptors in terms of expression and progesterone regulation could be different in control and PCOS hlGCs. We first confirmed that progesterone levels in both plasma (P < 0.0001) and follicular fluid (FF) (P < 0.0001) were significantly reduced in PCOS normal weight women compared to control women. These data were associated with a lower STAR mRNA expression in both in vivo (P < 0.0001) and in vitro (P < 0.0001) hlGCs from PCOS women. Secondly, chemerin FF levels (P < 0.0001) and RARRES2 (P < 0.05) and CMKLR1 (P < 0.0001) mRNA levels in GCs were higher in PCOS normal weight patients. Thirdly, treatment of hlGCs with a specific nanobody (the VHH CA4910) targeting the human receptor for CMKLR1 leading to its inactivation abolished chemerin-induced progesterone inhibition, suggesting the involvement of CMKLR1 in this process. Furthermore, the inhibition of progesterone secretion induced by chemerin was two-fold higher in PCOS hlGCs (P < 0.05). Moreover, the VHH CA4910 reinstated a normal progesterone secretion with lower concentrations in PCOS hlGCs, suggesting a different chemerin sensitivity between PCOS and control hlGCs. Thus, chemerin, through CMKLR1, could be involved in the steroidogenesis alterations in PCOS hlGCs.

Open article ↗



2021-08-27 | Rare deleterious BUB1B variants induce premature ovarian insufficiency and early menopause.

Losing of ovarian functions prior to natural menopause age causes female infertility and early menopause. Premature ovarian insufficiency (POI) is defined as the loss of ovarian activity before 40 years of age. Known genetic causes account for 25-30% of POI cases, demonstrating the high genetic heterogeneity of POI and the necessity for further genetic explorations. Here we conducted genetic analyses using whole-exome sequencing in a Chinese non-syndromic POI family with the affected mother and at least four affected daughters. Intriguingly, a rare missense variant of BUB1B c.273A>T (p.Gln91His) was shared by all the cases in this family. Furthermore, our replication study using targeted sequencing revealed a novel stop-gain variant of BUB1B c.1509T>A (p.Cys503*) in one of 200 sporadic POI cases. Both heterozygous BUB1B variants were evaluated to be deleterious by multiple in silico tools. BUB1B encodes BUBR1, a crucial spindle assembly checkpoint component involved in cell division. BUBR1 insufficiency may induce vulnerability to oxidative stress. Therefore, we generated a mouse model with a loss-of-function mutant of Bub1b, and also employed D-galactose-induced aging assays for functional investigations. Notably, Bub1b+/- female mice presented late-onset subfertility, and they were more sensitive to oxidative stress than wild-type female controls, mimicking the clinical phenotypes of POI cases affected by deleterious BUB1B variants. Our findings in human cases and mouse models consistently suggest, for the first time, that heterozygous deleterious variants of BUB1B are involved in late-onset POI and related disorders.

Open article ↗



2000-04-07 | The gamete fusion process is defective in eggs of Cd9-deficient mice.

The cell-surface molecule Cd9, a member of the transmembrane-4 superfamily, interacts with the integrin family and other membrane proteins. and is postulated to participate in cell migration and adhesion. Expression of Cd9 enhances membrane fusion between muscle cells and promotes viral infection in some cells. Fertilization also involves membrane fusion, between gametes. In mammals, the sperm binds to microvilli on the egg surface, and sperm-egg membrane fusion first occurs around the equatorial region of the sperm head12. The fused membrane is then disrupted, and the sperm nucleus as well as the cytoplasm is incorporated into the egg. Cd9 is expressed on the plasma membrane of the mouse egg, and an anti-Cd9 monoclonal antibody inhibits sperm-egg surface interactions. We generated Cd9 mice and found that homozygous mutant females were infertile. Sperm-egg binding was normal, but sperm-egg fusion was almost entirely inhibited in eggs from Cd9 females. Intracellular Ca2 oscillations, which signal fertilization, were absent in almost all mutant eggs; in rare cases, a response occurred after a long time period. In normal animals, Cd9 molecules were expressed on the egg microvilli and became densely concentrated at the sperm attachment site. Thus, our results show that Cd9 is important in the gamete fusion process at fertilization.

Open article ↗



small molecules
2026-09-23 | Arimoclomol-loaded Pluronic F127 nanomicelles in experimental endometriosis: drug incorporation, in vitro release, and early morphological and histological responses.

Endometriosis is a chronic, estrogen-dependent inflammatory disease characterized by ectopic endometrial-like glands and stroma, persistent pelvic inflammation, pain, infertility, and frequent recurrence. The limited availability of nonhormonal and lesion-directed therapies supports the investigation of alternative pharmacological mechanisms and regional drug-delivery strategies. Arimoclomol is a co-inducer of the endogenous heat-shock response with the capacity to amplify stress-dependent proteostasis, whereas Pluronic F127 is an amphiphilic PEO-PPO-PEO copolymer that forms drug-associated micellar assemblies in aqueous media. This exploratory study evaluated the physicochemical properties, in vitro release profile, and early biological response to arimoclomol-loaded Pluronic F127 nanomicelles in an autologous-transplantation rat model of endometriosis. The formulation was prepared by dispersing 30 mg of arimoclomol in 2 mL of Pluronic F127 at 20% (w/v), followed by stirring and ultrasonication under cooling. Because no centrifugation, filtration, dialysis, lyophilization, or other drug-removal step was applied after incorporation, the nominal process loading efficiency was 100%, based on formulation mass balance. The corresponding theoretical drug content was 6.98% w/w of total formulation solids and 7.5% w/w relative to the polymer mass. Drug-polymer association was supported by scanning electron microscopy coupled to energy-dispersive X-ray spectroscopy, Raman spectroscopy, and UV-Vis spectroscopy. In vitro dialysis at 37 °C showed a rapid increase in acceptor-medium arimoclomol concentration, reaching 14.33 ± 0.18 µg/mL at 2 h, followed by a progressive decline, with arimoclomol remaining detectable at 72 h (2.76 ± 0.04 µg/mL). Endometriosis was induced in ten female Wistar rats. On day 16, animals received a single intraperitoneal administration of arimoclomol-loaded nanomicelles (n = 4), empty nanomicelles (n = 3), or free arimoclomol (n = 3). The arimoclomol dose was 3 mg/animal, equivalent to approximately 14.7-16.8 mg/kg according to the recorded body-weight range. Twenty-four hours after treatment, representative lesions from the loaded-nanomicelle group appeared smaller macroscopically and showed mildly atrophic glands, stromal disorganization, and less prominent inflammatory infiltration than representative lesions from the empty-carrier and free-drug groups. All clinical welfare scores remained zero, and no overt short-term intolerance was observed. These findings demonstrate nominal quantitative drug retention based on process mass balance, a biphasic in vitro release pattern, and an early treatment-associated morphological and histological response. These preliminary findings require confirmation in larger, blinded, power-calculated studies with quantitative lesion endpoints, mechanistic biomarkers, lesion-specific pharmacokinetics, and longitudinal safety assessment.

Open article ↗



2026-09-14 | [A novel CYP19A1 variant causing aromatase deficiency in a family: case report and literature review].

Aromatase deficiency is a rare autosomal recessive disorder of estrogen biosynthesis caused by pathogenic variants in the CYP19A1 gene, located on chromosome 15q21.2. Maternal virilization during pregnancy serves as an important diagnostic clue. Affected females may present with virilized external genitalia at birth, and later in life may develop primary amenorrhea, ovarian cysts or ovarian dysplasia, delayed epiphyseal closure, and reduced bone mineral density. Herein, a family with aromatase deficiency admitted to the Department of Endocrinology and Metabolism at the Affiliated Hospital of Qingdao University in October 2020 is reported. The female proband exhibited virilized external genitalia since birth, along with hirsutism, acne, and voice deepening. Laboratory findings revealed low estrogen levels, hyperandrogenemia, and elevated follicle-stimulating hormone and luteinizing hormone levels. Genetic testing identified a homozygous CYP19A1 variant. After estrogen replacement therapy, the patient achieved regular menstrual cycles, with improvements in hirsutism and acne. A literature review identified 35 female patients carrying 28 distinct CYP19A1 variants, most of whom exhibited characteristic clinical manifestations. Whole-exome sequencing in the present case revealed a homozygous CYP19A1 variant, c.293_296+1delinsTTA, which has not been previously reported. Given the low incidence of aromatase deficiency, individualized treatment is cruical for optimal outcomes. Genetic testing plays a pivotal role in establishing a definitive diagnosis and guiding personalized management.

Open article ↗



2026-09-06 | Successful pregnancy after in vitro fertilization-embryo transfer in a patient with cytochrome P450 oxidoreductase deficiency and a double uterus: Case report.

Cytochrome P450 oxidoreductase deficiency (PORD) is a rare autosomal recessive disorder caused by mutations in the POR gene, leading to impaired steroid hormone synthesis and a wide range of multisystem abnormalities. The condition is often associated with reproductive malformations and endocrine disorders, presenting clinically with symptoms such as infertility, menstrual irregularities, and adrenal dysfunction, and may be accompanied by skeletal malformations. Only a very limited number of patients have achieved successful pregnancies through assisted reproductive technology, and there is currently no standardized treatment strategy. A 29-year-old woman presented with "7 years of infertility without contraception." Genetic analysis identified compound heterozygous POR mutations (c.1820A>G/c.1474G>A), confirming PORD. Pelvic imaging revealed uterus didelphys. Endocrine evaluation demonstrated insulin resistance and adrenal dysfunction, and the patient fulfilled the diagnostic criteria for polycystic ovary syndrome. Following unsuccessful long-protocol ovulation induction, a modified gonadotropin-releasing hormone antagonist protocol was implemented with metformin co-treatment for insulin sensitization. Stepwise glucocorticoid therapy (oral prednisone 5 mg/day → dexamethasone 0.5 mg/day → transition to hydrocortisone 20 mg/day during pregnancy) was administered for adrenal progesterone regulation. All embryos underwent vitrification, with subsequent single frozen-thawed blastocyst transfer. Ovarian stimulation yielded 24 oocytes, resulting in 7 blastocysts. Successful singleton implantation was achieved. The pregnancy progressed without maternal metabolic or fetal complications, culminating in term delivery (39 weeks and 4 days) of a healthy male neonate (birth weight 3250 g, Apgar scores 9/10). This case demonstrates that pregnancy attainment in complex PORD requires protocol individualization using gonadotropin-releasing hormone antagonists to mitigate premature luteinization, dynamic glucocorticoid titration to control adrenal steroid excess, and metabolic optimization addressing insulin resistance. The co-occurrence of POR mutations should be investigated in assisted reproductive technology failures with polycystic ovary syndrome-like presentations, particularly when accompanied by skeletal or genital tract anomalies.

Open article ↗



2026-07-31 | Utility of homoeopathic medicines in management of cases of PCOS - A retrospective hospital based study

Introduction: This comprehensive study evaluates the effectiveness of Homoeopathic medicines in the management of PCOS cases through a hospital based retrospective study & identifies frequently used Homoeopathic medicines and the prominent miasm in the reported outcomes. PCOS is a multisystem disorder on the rise in the last few years. It is marked by irregular menses, Hyperandrogenism, hirsutism, acne, infertility with global prevalence of 6% to 26%.Homoeopathy is a holistic system, which helps in this endocrine disorder. Aim:To identify utility of homoeopathic medicines,the predominant miasm in cases of PCOS/PCOD through retrospective hospital based study. Materials and methods: It includes analysis of 792 female patients treated in the last 3 years (January 2021 - January 2024) of reproductive age (12 to 50 years) from a Govt. homoeo Medical College & Hospital, Rajamahendravaram, India. The data collected in specifically designed formats the master charts and details shown in the form of Tables and charts. Results: Most patients presented with irregular menses, dysmenorrhea, acne, weight gain, hirsutism, and infertility. Individualized homoeopathic medicines, mainly polycrests were frequently used with positive outcomes including menstrual regularization in over 60% of cases. Antimiasmatics and rare remedies were also applied. The predominant miasm identified through retrospective study was psoro-sycotic. Conclusion: This retrospective study data indicates individualized/constitutional homoeopathic medicines like polycrests playing a significant role in managing PCOS symptoms, particularly menstrual irregularities and infertility. The predominant miasm identified is Psorosycotic, antimiasmatics complement treatment success. It shows that polycrests are proven effective in treating PCOS. There is a requirement for well documented case formats in hospital settings, well planned, pragmatic research studies and RCTs.

Open article ↗



2026-07-31 | Therapeutic Roles and Safety Profiles of Non-Vitamin Antioxidant Supplements in Female Infertility: A Narrative Review.

Treatment of female infertility consists different strategies including metabolic, hormonal and surgical therapeutic modalities. Non-vitamin supplements with antioxidant activity as carnitines, Inositols, Poly Unsaturated Fatty Acids (PUFAs), coenzyme Q10 and melatonin are among those with most popularity, but their prescription may confer some warnings. This review narrates the antioxidant mechanism of these supplements, beside their effect on outcomes of infertility treatment while considering side effects, warnings and ranges of doses. Carnitines are used for energy production and fat metabolism, while they have anti-aging and antioxidant effects. Supplementation with carnitines improve obesity outcomes, especially in Poly Cystic Ovarian Disease (PCOS) patients. Rare cases have shown increasing risk of seizure with levocarnitine. Coenzyme Q10 (Ubiquinone) has shown benefit in patients with PCOS or poor ovarian responders. It significantly increased live birth rate and the side effects are minimal even in higher doses. Poly Unsaturated Fatty Acids (PUFAs) have shown impact on follicular development and embryo quality. The hazard is increasing lipid low density lipoprotein (LDL) in high doses. Use of inositols in female infertility treatment is due to its metabolic effect and insulin resistance in PCOS patients resulting in decreasing use of gonadotropins. They have produced acceptable results about count of follicles and oocyte quality. Hypoglycemic effects of inositols have been reported as side effect, especially in combination with other hypoglycemic agents. Melatonin can increase the clinical pregnancy rate, and improve the outcomes about oocyte and quality of embryo via receptor- and non-receptor- action. Dizziness, drowsiness, and headache are reported in higher doses of melatonin. The attitude that all supplement can be prescribed without restriction endangers susceptible patients. Hence, increasing our knowledge about efficacy and safety profile can help individualize prescription of supplements for female infertility.

Open article ↗



proteins
2026-08-01 | EP1877 - LBA_ECE_1047 - FSH resistance syndrome in a young woman with primary amenorrhea

Abstract Introduction FSH-resistant ovary syndrome is a rare cause of primary or secondary amenorrhea. It is characterized by menopausal levels of FSH and LH, low estradiol levels, normal anti-Müllerian hormone (AMH) levels, and the presence of immature ovarian follicles with impaired maturation due to mutations in the FSH receptor (FSHR) gene. Patients present with anovulation and infertility and are commonly diagnosed with premature ovarian insufficiency. Case Presentation A 32-year-old woman with a history of primary amenorrhea presented for fertility evaluation. The patient had normal secondary sexual characteristics and had been treated with cyclic hormonal therapy with estrogen and progesterone since adolescence. Laboratory evaluation showed a normal female karyotype, elevated FSH/LH levels (101.9 mIU/mL and 41.4 mIU/mL, respectively), low estradiol levels (17.2 pg/mL), and normal AMH levels (1.7 ng/mL). Transvaginal ultrasound demonstrated normal internal genitalia, with an antral follicle count of 10. There was no known family history of infertility. The patient underwent ovarian stimulation with follitropin alfa 300 IU, without follicular development. Genetic testing revealed a novel homozygous missense variant in the FSHR gene, c.1412T>G p.(Ile471Ser), classified as likely pathogenic, confirming the diagnosis of FSH resistance syndrome. The patient was referred for further specialized assisted reproductive treatment. Conclusions FSH resistance should be suspected in women of reproductive age presenting with primary or secondary amenorrhea, when elevated FSH and LH levels are found alongside low/normal estradiol levels, but preserved ovarian reserve. The combination of clinical evaluation, laboratory findings, and genetic testing enables early recognition and appropriate counseling. In these cases, conventional ovarian stimulation has low likelihood of success, and recommended reproductive strategies include in vitro maturation (IVM) of oocytes and oocyte donation.

Open article ↗



2026-07-30 | Hemoperitoneum after oocyte retrieval in women undergoing ART: A 2017-2022 retrospective cohort study with a historical comparison to 1996-2016.

To estimate the incidence and predictors of severity-defined hemoperitoneum after oocyte retrieval in a contemporary 2017-2022 cohort, and to place these findings in context with the center's previously published 1996-2016 experience. Retrospective cohort study including all 13,192 oocyte retrieval procedures performed at a single fertility center from January 2017 to December 2022 in 9,346 women. The primary endpoint was documented hemoperitoneum associated with hemoglobin decrease ≥ 2 g/dL and/or hospital admission, surgery or blood transfusion. The 1996-2016 cohort was retained only as an aggregate historical comparator. Predictors were estimated with robust Poisson regression clustered by patient identifier. Severity-defined hemoperitoneum was identified among 50 retrievals (0.379 %), including 46 cases with hemoglobin decrease ≥ 2 g/dL, 44 admissions, 20 surgical procedures and 12 transfusions. The contemporary primary endpoint was recorded more frequently than the historical aggregate hemorrhagic comparator (RR 1.67, 95 % CI 1.14-2.46, p = 0.010), whereas surgery did not differ significantly (RR 1.81, 95 % CI 0.97-3.36, p = 0.069). In the primary contemporary model, lower BMI (RR 0.80 per kg/m2, 95 % CI 0.73-0.88, p < 0.001), higher AMH (RR 1.08, 95 % CI 1.02-1.14, p = 0.010) and longer total retrieval time (RR 1.03 per minute, 95 % CI 1.00-1.06, p = 0.044) were associated with severity-defined hemoperitoneum. Hemoperitoneum after oocyte retrieval was rare, but associated with substantial morbidity when it occurred. Lower BMI and higher AMH were the main patient-level risk markers. Total retrieval time remained modestly associated with the risk, and should be interpreted as a marker of ovarian response and procedural complexity. The higher rate observed in the contemporary cohort should be interpreted cautiously, as surgery did not increase significantly. NCT05895227, May 31st, 2023.

Open article ↗



2026-02-23 | The Clinico-radiological Perspective of Kartagener's Syndrome.

Kartagener's syndrome is a rare autosomal recessive genetic disorder, a subset of primary ciliary dyskinesia. It comprises the triad of situs inversus totalis, bronchiectasis, and chronic paranasal sinusitis. The incidence is 1:30,000 live births, while the male: female ratio is 1:1. Most patients of Kartagener's syndrome present in early childhood with common symptoms of frequent colds, chronic cough with excessive production of purulent sputum, and recurrent lower respiratory tract infections affecting respiratory functions. Kartagener's syndrome commonly presents as infertility in males and subfertility in females. We present the clinical and radiological findings in a patient of Kartagener's syndrome referred to us with recurrent lower respiratory tract infections.

Open article ↗



2026-01-31 | TURNER SYNDROME: CLINICAL FEATURES AND CONTEMPORARY DIAGNOSTIC APPROACHES

Turner syndrome (TS) is a rare chromosomal disorder affecting approximately 1 in 2,500–3,000 live female births and caused by complete or partial monosomy of one X chromosome, most commonly presenting as a 45, X karyotype or mosaic forms. The syndrome is associated with a wide spectrum of clinical manifestations, including short stature, ovarian dysgenesis, delayed puberty, infertility, and congenital anomalies, particularly cardiovascular malformations such as coarctation of the aorta and bicuspid aortic valve.

Open article ↗



2025-11-21 | Turner disease: A contemporary clinical approach

Turner syndrome (TS) is a rare genetic disorder in females caused by partial or complete loss of one X chromosome. It presents with multisystem clinical manifestations that require lifelong multidisciplinary care and monitoring. Phenotypically, TS is characterized by short stature, short neck with lateral skin folds (pterygium colli), low-set ears, and a low posterior hairline. Clinically, it is associated with cardiovascular diseases (CVD) and primary hypogonadism. The diagnosis of TS is based on clinical presentation and genetic analysis, with early prenatal detection possible. In newborns, TS should be suspected in the presence of oedema of the hands and feet. Short stature becomes evident in early childhood, while delayed puberty and primary amenorrhea are common later findings. CVDs may be congenital or acquired; coarctation of the aorta is a key diagnostic sign, whereas aortic dissection and rupture of an aortic aneurysm are life-threatening complications. Most women with TS have primary hypogonadism and high infertility rates. Spontaneous pregnancies are rare, and fertility preservation options, such as oocyte or embryo cryopreservation, should be considered early. Associated autoimmune diseases, kidney anomalies, liver disorders, and hearing loss are also common. Hormone replacement therapy is essential for pubertal induction, maintenance of general health, and prevention of long-term complications of untreated hypogonadism. Due to numerous comorbidities and variable phenotypes, an individualized multidisciplinary approach is required. With early diagnosis, appropriate management, and psychosocial support, individuals with TS can lead a good quality of life despite ongoing health risks.

Open article ↗



cell therapies
2026-03-10 | Reproductive Challenges of the Ageing Female: A Comprehensive Narrative Review.

Changes in societal norms over the last few decades have resulted in novel family planning trends, notably delayed childbearing and increased maternal age at the birth of the first child. Despite advances in reproductive medicine, ageing poses significant challenges. Natural conception in women ≥ 45 years of age is rare, with high rates of pregnancy loss, and assisted reproduction using autologous oocytes yields limited success. Oocyte donation offers higher live birth rates, exceeding 50%. Elective oocyte cryopreservation could aid in family planning; nevertheless, its success depends on the age at which cryopreservation is performed. These facts highlight the correlation between advancing age and a decline in oocyte quality and quantity. An age-related decline in endometrial receptivity could pose an additional barrier, although the evidence remains controversial. Furthermore, pregnancies in older women carry high risks for both the mother and child, which should be considered before assisted conception attempts. This comprehensive narrative review examines the advancements in assisted reproductive technology that have expanded the possibilities for delayed childbearing, while underlining at the same time the major challenges in the field. Innovations such as ovarian tissue cryopreservation and stem cell-based therapies have the potential to reshape reproductive options for these women. However, thorough counselling and tailored management remain of paramount importance.

Open article ↗



2025-12-12 | The Doing/Undoing of MRKH and the Doing of Gestational Pregnancy and Gender Through Uterus Transplants.

Women with the rare Mayer-Rokitansky-Kuster-Hauser (MRKH) syndrome are born without a uterus. Following international interviews with 34 women with MRKH and 15 surgeons and specialists, we explore how the usually invisible condition of MRKH is made visible and "done" through biomedicine. MRKH is highly medicalized, with much work undertaken to make MRKH bodies fit heteronormative standards. Some people with MRKH prefer to define themselves as intersex. Others undertake uterus transplants (UTx), to experience menstruation, gestation, and birth. UTx reconstructs their bodies to heteronormative expectations at the same time as it reinforces gendered identity as normative women, and potentially as mothers.

Open article ↗



2025-11-26 | Endometrial Injury and Its Rescue by Mesenchymal Stem Cells Is Dependent on Estrous Cycle Phase.

Asherman Syndrome (AS) is caused by injury to the endometrium leading to uterine scarring, decreased menstruation and infertility; it typically occurs after surgical curettage of the uterus. AS is treated surgically albeit with limited success. Administration of bone marrow-derived mesenchymal stem cells (MSCs) has recently been demonstrated to restore uterine function in AS; however, there is no data available on the role of the estrous cycle phase on outcomes. Here, we describe endometrial injury during estrus or diestrus, its differential effect on fertility, and its response after bone marrow MSC treatment to reverse the infertility in a murine model. Endometrial injury in the estrus phase did not affect fertility outcomes whereas injury in the diestrus phase resulted in infertility. Bone marrow (BM)-derived MSC treatment without injury in the estrus or diestrus phase did not affect the pregnancy outcomes. BM MSC treatment following endometrial injury in the diestrus phase restored fertility. Immunofluorescence analysis revealed that vimentin or cytokeratin-positive BM-derived cells in the uterus were extremely rare. BM MSC treatment after injury increased CD45+ cells, indicating a role for immunomodulation in endometrial repair. Finally, qRT-PCR showed that Ccl3, Il-1β and Mmp3 gene expression was significantly higher in the endometrium of the injury + BM MSC group than in other groups. In summary, injury to the endometrium during the diestrus phase results in infertility that can be restored by the treatment of BM MSCs. The therapeutic effect of BM MSCs on the endometrium appears to be mediated primarily by immunomodulation rather than BM MSC engraftment.

Open article ↗



2025-11-18 | The Danish Turner Syndrome Cryopreservation study: PROTOCOL for a prospective cohort Study on reproductive outcomes after ovarian tissue cryopreservation in girls with Turner syndrome.

BACKGROUND: Turner syndrome (TS) is a chromosomal disorder caused by complete or partial loss of one X chromosome, resulting in a high risk of premature ovarian insufficiency (POI) and infertility. While the underlying mechanisms are not fully understood, oocyte loss is known to begin in fetal life and continue throughout childhood, often leading to ovarian failure before the onset of puberty. Ovarian tissue cryopreservation (OTC) offers a potential method to preserve fertility in girls with TS, but the procedure remains experimental in this group. To date, only three cases of autotransplantation have been reported, and no live births have occurred in women with TS. Moreover, predictors of residual ovarian function and eligibility for OTC are poorly defined, and the long-term effects of unilateral oophorectomy in girls with already limited ovarian reserve are unknown. OBJECTIVE: To investigate long-term reproductive outcomes following OTC in girls with TS. METHODS: The Danish Turner Syndrome Cryopreservation Study is a nationwide, prospective cohort study with long-term follow-up, combining observational and interventional elements. Girls with TS aged 2–17 years are invited to participate. As ovarian reserve is depleted before adulthood in most girls with TS, all participants undergo ovarian function assessment to evaluate the likelihood of remaining viable follicles. If follicles are deemed present, unilateral OTC may be offered. The primary outcome is the number of pregnancies, miscarriages, and live births following autotransplantation of cryopreserved and thawed ovarian tissue in adulthood. Secondary objectives include identifying early predictors of POI, assessing the impact of oophorectomy on ovarian function and pubertal progression, and exploring molecular mechanisms of ovarian dysgenesis through genetic and epigenetic analyses of ovarian and peripheral tissues. Recruitment began in January 2024 and is ongoing at three university hospitals across Denmark. Follow-up is expected to continue until 2050. CONCLUSION: This study addresses a critical gap in fertility preservation for girls with TS by evaluating the feasibility and long-term outcomes of OTC. The findings will improve understanding of POI progression, refine selection criteria for OTC, and support evidence-based counselling for girls with TS and their families. TRIAL REGISTRATION: ClinicalTrials.gov, NCT05740579. Registered 13 February 2023. https//clinicaltrials.gov/study/NCT05740579.

Open article ↗



2025-08-20 | A rare association of Craniopharyngioma and Meyer-Rokitansky-Kuster-Hauser Syndrome in a patient with primary amenorrhea and delayed puberty – A Case Report

Background: Meyer-Rokitansky-Kuster-Hauser Syndrome (MRKH) is a congenital abnormality of the uterus and the upper two-thirds of the vagina in women showing normal development of secondary sexual characteristics with a normal karyotype of 46, XY. Craniopharyngioma is a rare intracranial neoplasm found in seller/suprasellar region with two distinct histologic phenotypes – adamantinoma Tous and papillary. It has insidious onset of symptoms and presents as headache, visual impairment and hormonal imbalances secondary to compression of adjacent pituitary manifesting commonly as sexual dysfunction in adults and growth failure in children. This case report presents a 20 years female with primary amenorrhea and absence of secondary sex characteristics, headache and visual field defect who was subsequently diagnosed as adamant nous craniopharyngioma with multiple pituitary hormones deficiency with Type 1 MRKH. Patient underwent transsphenoidal resection and replacement of levothyroxine and corticosteroid with further plan of reassessing pituitary gonadal axis, creation of a neovagina, addressing puberty induction and infertility (in vitro fertilization and surrogacy). It is too early to say that there may be an association between craniopharyngioma and MRKH. Whether craniopharyngioma and MRKH share a similar etiology is unclear. With increasing genetic testing, in the future, we may get some correlation.

Open article ↗



gene therapies
2023-11-21 | Homozygous missense variant in MEIOSIN causes premature ovarian insufficiency.

Are variants of genes involved in meiosis initiation responsible for premature ovarian insufficiency (POI)? A MEIOSIN variant participates in the pathogenesis of human POI by impairing meiosis due to insufficient transcriptional activation of essential meiotic genes. Meiosis is the key event for the establishment of the ovarian reserve, and several gene defects impairing meiotic homologous recombination have been found to contribute to the pathogenesis of POI. Although STRA8 and MEIOISN variants have been found to associate with POI in a recent study, the condition of other meiosis initiation genes is unknown and direct evidence of variants participating in the pathogenesis of POI is still lacking. This was a retrospective genetic study. An in-house whole exome sequencing (WES) database of 1030 idiopathic POI patients was screened for variations of meiosis initiation genes. Homozygous or compound heterozygous variations of genes involved in meiosis initiation were screened in the in-house WES database. The pathogenicity of the variation was verified by in vitro experiments, including protein structure prediction and dual-luciferase reporter assay. The effect of the variant on ovarian function and meiosis was demonstrated through histological analyses in a point mutation mouse model. One homozygous variant in MEIOSIN (c.1735C>T, p.R579W) and one in STRA8 (c.258 + 1G>A), which initiates meiosis via the retinoic acid-dependent pathway, were identified in a patient with idiopathic POI respectively. The STRA8 variation has been reported in the recently published work. For the MEIOSIN variation, the dual-luciferase reporter assay revealed that the variant adversely affected the transcriptional function of MEIOSIN in upregulating meiotic genes. Furthermore, knock-in mice with the homologous mutation confirmed that the variation impacted the meiotic prophase I program and accelerated oocyte depletion. Moreover, the variant p.R579W localizing in the high-mobility group (HMG) box domain disrupted the nuclear localization of the MEIOSIN protein but was dispensable for the cell-cycle switch of oocytes, suggesting a unique role of the MEIOSIN HMG box domain in meiosis initiation. Further studies are needed to explore the role of other meiosis initiation genes in the pathogenesis of POI. The MEIOSIN variant was verified to cause POI by impaired transcriptional regulation of meiotic genes and was inherited by a recessive mode. The function of HMG box domain in MEIOSIN protein was also expanded by this study. Although causative variations in meiotic initiation genes are rare in POI, our study confirmed the pathogenicity of a MEIOSIN variant and elucidated another mechanism of human infertility. This work was supported by the National Key Research & Developmental Program of China (2022YFC2703800, 2022YFC2703000), National Natural Science Foundation for Distinguished Young Scholars (82125014), National Natural Science Foundation of China (32070847, 32170867, 82071609), Basic Science Center Program of NSFC (31988101), Natural Science Foundation of Shandong Province for Grand Basic Projects (ZR2021ZD33), Natural Science Foundation of Shandong Province for Excellent Young Scholars (ZR2022YQ69), Taishan Scholars Program for Young Experts of Shandong Province (tsqn202211371), and Qilu Young Scholars Program of Shandong University. The authors declare no conflict of interest. N/A.

Open article ↗



2019-07-15 | Novel WEE2 gene variants identified in patients with fertilization failure and female infertility.

To determine whether variants in the WEE2 (WEE1 homolog 2, also known as WEE1B) gene, which has been known to function in the formation of pronuclei during fertilization, contribute to fertilization failure. Case-control genetic study. University hospital. Ninety infertile women with repeated cycles of pronucleus formation failure undergoing in vitro fertilization and/or intracytoplasmic sperm injection treatment as well as 200 fertile control women. Genomic DNA was extracted from the peripheral blood. The whole exons of WEE2 were amplified by means of polymerase chain reaction and then Sanger sequencing was performed. Variants analysis of WEE2 gene. We identified five subjects that were subjected to homozygous or compound-heterozygous variants of WEE2: case 1 (from a consanguineous family) with homozygous frameshift variant: c.293_294insCTGAGACACCAGCCCAACC (p.Pro98Pro fsX2); case 2 with homozygous missense variant: c.1576T>G (p.Tyr526Asp); and three cases with compound-heterozygous variants: case 3: c.991C>A (p.His331Asn) and c.1304_1307delCCAA (p.Thr435Met fsX31); case 4: c.341_342 del AA (p.Lys114Asn fsX20) and c.864G>C (p.Gln288His); and case 5: c.1A>G (p.0?) and c.1261G>A (p.Gly421Arg). Besides c.1576T>G (from case 2) and c.864G>C (from case 4), which have been previously reported as rare single nucleotide polymorphisms (SNPs), the other six variants were novel and predicted by software to be deleterious. The parental genotypes of case 1 and case 2 indicated that the detected homozygous variants were inherited in an autosomal recessive mode. All of the detected variants were absent from the control cohort. Novel variants found in WEE2, which is autosomal-recessive inherited, may be related to recurrent pronucleus formation failure and female infertility.

Open article ↗



2018-03-16 | A Novel FOXL2 Mutation Implying Blepharophimosis-Ptosis-Epicanthus Inversus Syndrome Type I.

Blepharophimosis-ptosis-epicanthus inversus syndrome (BPES) is a rare autosomal dominant disease caused by FOXL2 gene mutations, and it is clinically characterized by an eyelid malformation associated (type I) or not (type II) with premature ovarian failure (POF). Functional study of novel mutations is especially critical for female patients, as it may allow the prediction of infertility and early planning of an appropriate therapy. A clinical and molecular genetic investigation was performed in all members of a Chinese family with BPES. Genomic DNA was extracted, and the FOXL2 coding region was sequenced. Subcellular localization was performed by confocal microscopy. Transactivation studies were performed by real-time PCR, dual luciferase reporter assays and electrophoretic mobility shift assays. A novel deletion mutation (C.634_641 del, CCCATGC) between the forkhead domain and the polyalanine domain was found, resulting in a frameshift mutation and a truncated protein. Functional studies showed a strong cytoplasmic mislocalization and abnormal transactivation activity, implying a type I kind mutation with a large chance of infertility. This study identifies that this mutation indicates the probability of developing into POF and shows the importance and necessity of early recognition of BPES type through mutation testing for female patients. Prompt personalized therapy and follow-up is of great clinical significance for female patients carrying this kind of mutation.

Open article ↗



2012-01-12 | Two common polymorphisms in the peroxisome proliferator-activated receptor γ gene may improve fertilization in IVF.

Genetic factors play an important role in women's fertility and embryonic development and may also contribute to the efficacy of assisted reproduction techniques. The aim of this study was to investigate the effect of His447His and Pro12Ala peroxisome proliferator-activated receptor γ (PPARγ) gene polymorphisms on oocytes and fertilization in women undergoing IVF. Follicular fluid and blood samples were obtained from 98 IVF patients referred to Tabriz Alzahra Hospital. Samples were analysed for fatty acid content by gas-liquid chromatography and for polymorphisms of the PPARγ gene using polymerase chain reaction-restriction fragment length polymorphism-based methods. Multiple regression analyses were used to test the independence of associations between the number of mature and fertilized oocytes as outcome variables and the polymorphisms of PPARγ gene. For both polymorphisms, fertilization ratio was significantly (P<0.05) higher in carriers of the rare alleles than homozygous wild-type genotypes. The associations of His447His (P=0.003) and Pro12Ala (P=0.015) polymorphisms remained statistically significant in the multiple regression analyses. This study suggests that the two common gene polymorphisms of PPARγ may improve fertilization in vitro and, thus possibly, female fertility.

Open article ↗



other
2022-08-02 | Biallelic variants in MOS cause large polar body in oocyte and human female infertility.

What is the genetic basis of female infertility involving abnormal oocyte morphology with the production of a large first polar body (PB1)? The homozygous missense variant (c.791C>G) and compound missense variants (c.596A>T and c.875C>T) in MOS proto-oncogene, serine/threonine kinase (MOS) (Online Mendelian Inheritance in Man (OMIM) reference: 190060; NM_005372.1) are responsible for abnormal oocyte morphology with the production of a large PB1 to cause infertility in women. MOS, an oocyte-specific gene, encodes a serine/threonine-protein kinase that directly phosphorylates mitogen-activated protein kinase (MAPK) kinase (MEK) to activate MAPK (also called extracellular-signal-regulated kinase (ERK)) signal cascade in the oocyte. Female mice lacking Mos remained viable, but infertile because of oocyte symmetric division, spontaneous parthenogenetic activation and early embryonic arrest. Recently, two independent studies demonstrated that female infertility with early embryonic arrest and fragmentation can be caused by biallelic mutations in MOS. However, so far, MOS variants have not been associated with the phenotype of large PB1 extrusion in human oocytes to contribute to female infertility. Two independent infertile families characterized by the presence of large PB1 in oocytes were recruited between December 2020 and February 2022. Genomic DNA was extracted from the peripheral blood samples of the subjects for whole-exome sequencing. Pedigree analysis was validated by Sanger sequencing. Then, the pathogenic effects of the MOS variants on MOS protein properties and ERK1/2 activation were determined in HEK293 cells and mouse oocytes. We identified three rare missense variants in MOS, including a homozygous missense variant (c.791C>G) from Patient 1 in Family 1 and two compound missense variants (c.596A>T and c.875C>T) from twin sisters in Family 2. The MOS variants followed a recessive inheritance pattern in infertile patients. All three patients displayed a high percentage of large PB1 extrusion in the oocytes. The three MOS variants could not activate MEK1/2 and ERK1/2 in oocytes and HEK293 cells. In addition, when compared with wild-type MOS, the MOS variants decreased the MOS protein level and attenuated the binding capacity with MEK1. Microinjection of wild-type human MOS complementary RNAs (cRNAs) reversed the symmetric division of oocytes after siMos treatment. In contrast, the three MOS variants demonstrated no rescuing ability. N/A. Owing to the scarcity of human oocyte samples and the associated ethical restrictions, we could not perform the rescue attempt for the study patients. Our findings expand the genetic and phenotypic spectrum of MOS variants in causing female infertility. Our study findings facilitate the early genetic diagnosis of abnormal oocyte morphology characterized as large PB1 that eventually causes infertility in women. This study was supported by the National Natural Science Foundation of China (82071640 and 82001633), Natural Science Foundation of Zhejiang Province (LD22C060001), the Key Projects Jointly Constructed by the Ministry and the Province of Zhejiang Medical and Health Science and Technology Project (WKJ-ZJ-2005), China Postdoctoral Science Foundation (2020M682575 and 2021T140198), the Changsha Municipal Natural Science Foundation (kq2007022) and Hunan Provincial Grant for Innovative Province Construction (2019SK4012). None of the authors declare any competing interests. N/A.

Open article ↗



2022-05-30 | Obstetrical complications and outcome in patients with endometriosis.

Endometriosis is a disease that has a profound impact on the quality of life of women, due to the associated chronic pelvic pain, dysmenorrhea, dyspareunia and infertility. However, even getting long-awaited pregnancy (often after assisted reproductive technologies), patients with endometriosis have a high risk of obstetric complications, such as miscarriage, preterm birth, preeclampsia, placental abnormalities, hemorrhage in labor, birth of small for gestational age infants, stillbirth and higher cesarean section rate. In addition, during pregnancy acute complications of endometriosis may occur, such as spontaneous hemoperitoneum, which is rare but life-threatening conditions that in most cases require surgical intervention. The mechanisms of the observed complications in pregnant women with endometriosis are not fully understood. This review presents literature data and personal considerations on the effect of endometriosis on pregnancy outcome and the occurrence of complications, as well as their possible underlined mechanisms. Based on this, we proposed ways to reduce the risk of obstetric complications in pregnant women with a history of endometriosis.

Open article ↗



2022-03-11 | Involvement of chemerin and CMKLR1 in the progesterone decrease by PCOS granulosa cells.

Polycystic ovarian syndrome (PCOS) is the main cause of infertility in women. It is frequently associated with reduced progesterone production by human luteinised granulosa cells (hlGCs). However, the molecular mechanisms involved in these steroidogenesis alterations in PCOS patients are unclear. In a dihydrotestosterone-induced PCOS mouse model, steroid production is maintained in the setting of chemokine-like receptor 1 (Cmklr1) knockout. Thus, chemerin and chemerin receptors in terms of expression and progesterone regulation could be different in control and PCOS hlGCs. We first confirmed that progesterone levels in both plasma (P < 0.0001) and follicular fluid (FF) (P < 0.0001) were significantly reduced in PCOS normal weight women compared to control women. These data were associated with a lower STAR mRNA expression in both in vivo (P < 0.0001) and in vitro (P < 0.0001) hlGCs from PCOS women. Secondly, chemerin FF levels (P < 0.0001) and RARRES2 (P < 0.05) and CMKLR1 (P < 0.0001) mRNA levels in GCs were higher in PCOS normal weight patients. Thirdly, treatment of hlGCs with a specific nanobody (the VHH CA4910) targeting the human receptor for CMKLR1 leading to its inactivation abolished chemerin-induced progesterone inhibition, suggesting the involvement of CMKLR1 in this process. Furthermore, the inhibition of progesterone secretion induced by chemerin was two-fold higher in PCOS hlGCs (P < 0.05). Moreover, the VHH CA4910 reinstated a normal progesterone secretion with lower concentrations in PCOS hlGCs, suggesting a different chemerin sensitivity between PCOS and control hlGCs. Thus, chemerin, through CMKLR1, could be involved in the steroidogenesis alterations in PCOS hlGCs.

Open article ↗



2021-08-27 | Rare deleterious BUB1B variants induce premature ovarian insufficiency and early menopause.

Losing of ovarian functions prior to natural menopause age causes female infertility and early menopause. Premature ovarian insufficiency (POI) is defined as the loss of ovarian activity before 40 years of age. Known genetic causes account for 25-30% of POI cases, demonstrating the high genetic heterogeneity of POI and the necessity for further genetic explorations. Here we conducted genetic analyses using whole-exome sequencing in a Chinese non-syndromic POI family with the affected mother and at least four affected daughters. Intriguingly, a rare missense variant of BUB1B c.273A>T (p.Gln91His) was shared by all the cases in this family. Furthermore, our replication study using targeted sequencing revealed a novel stop-gain variant of BUB1B c.1509T>A (p.Cys503*) in one of 200 sporadic POI cases. Both heterozygous BUB1B variants were evaluated to be deleterious by multiple in silico tools. BUB1B encodes BUBR1, a crucial spindle assembly checkpoint component involved in cell division. BUBR1 insufficiency may induce vulnerability to oxidative stress. Therefore, we generated a mouse model with a loss-of-function mutant of Bub1b, and also employed D-galactose-induced aging assays for functional investigations. Notably, Bub1b+/- female mice presented late-onset subfertility, and they were more sensitive to oxidative stress than wild-type female controls, mimicking the clinical phenotypes of POI cases affected by deleterious BUB1B variants. Our findings in human cases and mouse models consistently suggest, for the first time, that heterozygous deleterious variants of BUB1B are involved in late-onset POI and related disorders.

Open article ↗



2000-04-07 | The gamete fusion process is defective in eggs of Cd9-deficient mice.

The cell-surface molecule Cd9, a member of the transmembrane-4 superfamily, interacts with the integrin family and other membrane proteins. and is postulated to participate in cell migration and adhesion. Expression of Cd9 enhances membrane fusion between muscle cells and promotes viral infection in some cells. Fertilization also involves membrane fusion, between gametes. In mammals, the sperm binds to microvilli on the egg surface, and sperm-egg membrane fusion first occurs around the equatorial region of the sperm head12. The fused membrane is then disrupted, and the sperm nucleus as well as the cytoplasm is incorporated into the egg. Cd9 is expressed on the plasma membrane of the mouse egg, and an anti-Cd9 monoclonal antibody inhibits sperm-egg surface interactions. We generated Cd9 mice and found that homozygous mutant females were infertile. Sperm-egg binding was normal, but sperm-egg fusion was almost entirely inhibited in eggs from Cd9 females. Intracellular Ca2 oscillations, which signal fertilization, were absent in almost all mutant eggs; in rare cases, a response occurred after a long time period. In normal animals, Cd9 molecules were expressed on the egg microvilli and became densely concentrated at the sperm attachment site. Thus, our results show that Cd9 is important in the gamete fusion process at fertilization.

Open article ↗



Access all drug discovery papers and probability of success in trials forecasts:

Access all drug discovery papers and probability of success in trials forecasts:

Drug Discovery Landscape

1 orphan drug designation for Rare female infertility.

1 orphan drug designation for Rare female infertility.

Drug

Therapy type

Orphan designation

Clinical trial status

Sponsor

autologous adult bone marrow-derived and unexpanded CD133+ hematopoietic stem cells (CD133+ BMDSCs) mobilized from peripheral blood (PB)

cell therapies

FDA
2019-02-01

Phase I/II
Ongoing

Asherman Therapy S.L.U.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.